Apellis Pharmaceuticals, Inc. (APLS)

47.53 +0.02 (+0.04%) At close: 04:00PM EDT

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 702

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Cedric Francois M.D., Ph.D.	Co-Founder, President, CEO & Director	1.2M	2.36M	1972
Dr. Pascal Deschatelets Ph.D.	Co-Founder & Chief Scientific Officer	688.05k	8.37M	1970
Mr. Alec Machiels J.D., MBA	Co-Founder & Director	72.5k	N/A	1973
Mr. Timothy E. Sullivan	CFO & Treasurer	716.41k	N/A	1971
Mr. Adam J. Townsend	Chief Operating Officer	701.61k	3.2M	1978
Mr. David O. Watson Esq., J.D.	General Counsel	675.35k	N/A	1973
Mr. James G. Chopas CPA	VP, Corporate Controller & Chief Accounting Officer	N/A	N/A	1967
Ms. Meredith Kaya	Senior Vice President, Investor Relations & Strategic Finance	N/A	N/A	N/A
Ms. Karen Lewis	Chief People Officer	N/A	N/A	1973
Prof. Peter Hillmen M.D., Ph.D.	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate Governance

Apellis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.